Product Code: RP-ID-10080125 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10080125
Market Overview:
Cardiovascular Pharmaceuticals Market Analysis by Drug Class (Anti-Hypertensives, Anti-Coagulants, and Anti-Hyperlipidemic Drugs); by Indication (Hypertension, Arrhythmia, Coronary Artery Disease, and Hyperlipidemia); and by Distribution Channel (Retail pharmacies, E-pharmacies, and Others)-Global Supply & Demand Analysis & Opportunity Outlook 2023-2033
Global Cardiovascular Pharmaceuticals Market Definition
Cardiovascular diseases are the class of diseases which directly affects the heart or blood vessels. It includes coronary artery diseases, such as angina and heart attack. Other forms of cardiovascular disease involve, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, congenital heart disease and others. They can be prevented by taking intensive care of hearts which involves healthy eating, exercise, avoidance of tobacco, and limiting alcohol intake. Taking precautions with risk factors such as, high blood pressure, blood lipids and diabetes in people can also help in improving health of the heart and minimizes the chances of cardiovascular diseases.
Global Cardiovascular Pharmaceuticals Market: Key Insights
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~5% |
|
Base Year Market Size (2022) |
~ USD 156 Billion |
|
Forecast Year Market Size (2033) |
~ USD 234 Billion |
|
Regional Scope |
|
Global Cardiovascular Pharmaceuticals Market Highlights Over 2023 - 2033
The global cardiovascular pharmaceuticals market is estimated to garner a revenue of USD 234 Billion by the end of 2033 by growing at a CAGR of ~5% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of USD 156 Billion in the year 2022. The growth of the market can be attributed to burgeoning rate of cardiovascular disease (CVDs) worldwide. As per the World Health Organization 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Policymakers are leveraging health care price transparency as a potential strategy to curb rising health care costs.
Global Cardiovascular Pharmaceuticals Market Highlights Over 2023 - 2033
The global cardiovascular pharmaceuticals market is estimated to garner a revenue of USD 234 Billion by the end of 2033 by growing at a CAGR of ~5% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of USD 156 Billion in the year 2022. The growth of the market can be attributed to burgeoning rate of cardiovascular disease (CVDs) worldwide. As per the World Health Organization 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Policymakers are leveraging health care price transparency as a potential strategy to curb rising health care costs.
GET A SAMPLE COPY OF THIS REPORT
Cardiovascular pharmaceuticals are prescribed to treat hypertension and dyslipidemia as these conditions are largely to blame for the development of atherosclerotic plaque in blood vessels, which restricts blood flow to various body parts and causes a variety of cardiac symptoms including stroke, heart failure, cardiomyopathy, peripheral artery disease, and venous thrombosis. Cardiovascular drugs are used to treat heart and blood vessel diseases, which are among the world's major causes of mortality. As per the estimates of World Health Organization annually, 15 million people worldwide suffer a stroke. Of these, 5 million die and another 5 million are left permanently disabled.
Global Cardiovascular Pharmaceuticals Market: Growth Drivers and Challenges
Growth Drivers
-
Rising Demand for More Effective Cardiovascular Drugs – According to World Health Organization at least 50% of eligible people should receive drug therapy and counselling (including glycaemic control) to prevent heart attacks and strokes by 2025.
-
Growing Investment in Research and Drug Development- Approximately USD 84 billion was spent in R&D in 2019 by the pharmaceutical industry.
-
Rising Hospitalization and Number of Admissions in Critical Care Units- As per the estimates approximately 3000 hospital admissions took place in 2018 for cardiac issues.
-
Increasing Prevalence of Heart Failure- Furthermore, heart failure affects at least 27 million people globally.
Challenges
-
Adverse Effects of Cardiovascular Medication – Side effects of the medicines on the health of people is likely to affect the market growth.
-
Expiration of Several Medications Patents
-
High Cost of Cardiovascular Drugs
The global cardiovascular pharmaceuticals market is segmented and analyzed for demand and supply by indication into hypertension, arrhythmia, coronary artery disease, and hyperlipidemia. Out of these, the hypertension segment is expected to hold the largest share over the forecast period in the global cardiovascular pharmaceuticals market. This can be attributed to the increase in blood pressure resulting from unhealthy lifestyle. According to World Health Organization hypertension or elevated blood pressure is a serious medical condition that significantly increases the risks of heart, brain, kidney and other diseases.
Global Cardiovascular Pharmaceuticals Market Regional Synopsis
Regionally, the global cardiovascular pharmaceuticals market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in North America is projected to hold the largest market share by the end of 2033. This can be attributed to the rise in diabetes cases in the region. Furthermore, an increase in the number of new products is expected to fuel the market growth during the forecast period. Approximately 1 million Americans are diagnosed with diabetes every year.
Market Segmentation
Our in-depth analysis of the global cardiovascular pharmaceuticals market includes the following segments:
|
By Drug Class |
|
|
By Indication |
|
|
By Distribution Channel |
|
Key Companies Dominating the Global Cardiovascular Pharmaceuticals Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global cardiovascular pharmaceuticals market that are included in our report are Bristol-Myers Squibb Company, Bayer AG, Pfizer Inc., Janssen Pharmaceuticals, Inc., Novartis AG, Merck & Co., AstraZeneca plc, Sanofi S.A., Gilead Sciences, Inc., F. Hoffmann-La Roche, and others.
Global Cardiovascular Pharmaceuticals Market: Latest Developments
-
August, 2022: Gilead Sciences, Inc. - announced the approval from European Commission (EC) for the usage of lenacapavir injection and tablets for the treatment of HIV infection.
-
October, 2022-: Pfizer Inc. - announced completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company that offers hope to underserved patient communities beginning with sickle cell illness (SCD).
1. AstraZeneca Pharma India Limited
2. Aventis Pharma Limited
3. Cipla Limited
4. Dr. Reddy's Laboratories Limited
5. GlaxoSmithKline Pharmaceuticals Limited
6. Lupin Limited
7. Merck Limited
8. Novartis India Limited
9. Pfizer Limited
10. Ranbaxy Laboratories Limited
11. Sun Pharmaceutical Industries Limited
12. Torrent Pharmaceuticals Limited
13. Bristol-Myers Squibb India Private Limited
14. Cadila Pharmaceuticals Limited
15. Intas Pharmaceuticals Limited
16. USV Limited
Related Reports
Proof of Quality & Reliability
